Supporting a potential role for fibulin-2 in malignant progression, global transcriptomic profiling of diverse types of human adenocarcinoma revealed that fibulin-2 was more highly expressed in metastatic tumors than it was at primary sites [10], and a proteomic screen of highly and poorly metastatic tumor cell lines derived from mice that develop lung adenocarcinoma owing to co-expression of KrasG12D and Trp53R172HΔG (designated “KP” cells and mice, respectively) revealed that fibulin-2 was preferentially expressed in highly metastatic cells [11]. The gene discussed is FBLN2; the disease is adenocarcinoma.